微RNA-92a (miR-92a) 可能成为多种癌症中的一种新的有前途的生物标志物，包括结直肠癌 (CRC)；然而，miR-92a 在 CRC 中的诊断准确性和潜在的分子机制还不清楚。我们首先进行了meta分析，发现血清/血浆miR-92a 相对粪便样本和 CRC 组织，具有更好的诊断效果，这一发现又通过我们的小便样本的独立研究得到了验证。多个生物信息学分析表明，miR-92a 的表达与异质核糖核蛋白A2/B1 (HNRNPA2B1) 的表达呈正相关，并与 CRC 的临床特征密切相关。实验证据显示，在 RKO 细胞中降低 HNRNPA2B1 的表达可以显著降低miR-92a 的表达和分泌。HNRNPA2B1通过m6 A RNA修饰介导miR-92a 的表达。这些发现表明，HNRNPA2B1-m6A RNA修饰导致的MicroRNA-92a的上调和分泌来自局部CRC，是结直肠癌的一种候选非侵入性血清生物标志物。我们的研究提供了miR-92a在CRC诊断中表达和分泌机制方面的新见解。

MicroRNA-92a (miR-92a) may serve as a novel promising biomarker in multiple cancers, including colorectal cancer (CRC); however, the diagnostic accuracy and the underlying molecular mechanism of miR-92a in CRC is poorly understood. We first carried out meta-analysis and found that serum/plasma miR-92a yield better diagnostic efficacy when compared to stool samples and CRC tissues, and this finding was validated by our independent study through stool sample. Multiple bioinformatics assay indicated that miR-92a expression was positively correlated with heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) expression and closely related with the clinical characteristics of CRC. Experimental evidence showed that knockdown of HNRNPA2B1 could significantly decrease miR-92a expression and secretion in RKO cells. HNRNPA2B1 mediated miR-92a via m6A RNA modification. These findings indicate that HNRNPA2B1-m6A RNA modification-derived MicroRNA-92a upregulation and section from the local CRC acts a candidate noninvasive serum biomarker in colorectal cancer. Our study provides a novel insight into miR-92a mechanisms in relation to both expression and secretion for CRC diagnosis.